Metastatic Lung Cancer Clinical Trials 2023

Metastatic Lung Cancer Clinical Trials 2023

Metastatic Lung Cancer research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in metastatic lung cancer clinical trials today.

Trials for NSCLC Patients

Trials for Non-Small Cell Lung Cancer Patients

Trials for EGFR Positive Patients

Trials for ALK Positive Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to metastatic lung cancer

What are the top hospitals conducting metastatic lung cancer research?

In the battle against metastatic lung cancer, several hospitals are leading the charge in pioneering clinical trials. At the University of California Davis Comprehensive Cancer Center in Sacramento, researchers are currently conducting seven active trials focused on this aggressive form of cancer. Their commitment to finding innovative treatments is evident through their impressive 62 previous trials dedicated to metastatic lung cancer since embarking on their first study in 2006. Similarly, UC San Diego Moores Cancer Center in La Jolla is actively engaged in six ongoing trials for metastatic lung cancer and has a respectable track record with 45 completed studies dating back to their inaugural trial in 2009.

Meanwhile, at Sutter Roseville Medical Center located in Roseville, a dedicated team of experts is undertaking five active clinical trials targeting metastatic lung cancer. Over the years, they have accumulated valuable knowledge from their involvement in 31 past investigations since commencing research efforts into this condition back in 2004. Additionally contributing to advancements within this field are Sutter Cancer Centers Radiation Oncology Services-Auburn and Sutter Cancer Centers Radiation Oncology Services-Cameron Park; both facilities offer valuable opportunities for patients to participate in cutting-edge research as they each conduct five ongoing clinical trials related to metastatic lung cancer while having previously conducted eighteen such studies starting from the year2008

These hospitals represent beacons of hope for those affected by advanced-stage lung cancer by pushing boundaries and expanding our understanding of treatment options available. Through these collective endeavors across various locations within California's healthcare landscape lies an unwavering determination towards finding innovative approaches that could potentially transform outcomes for patients facing metastatic lung cancer.

Which are the best cities for metastatic lung cancer clinical trials?

When it comes to metastatic lung cancer clinical trials, several cities have emerged as prominent hubs of research and innovation. Sacramento, California leads the way with 29 active trials investigating treatments such as Crizotinib, High Radiation Dose Therapy, and Subprotocol C2 (MET exon 14 deletion/mutation). Anchorage, Alaska closely follows with 25 ongoing studies focusing on therapies like High Radiation Dose Therapy and Crizotinib. New york City also plays a significant role in this field with 23 active trials exploring treatments including Amivantamab and brigimadlin (BI 907828) treatment arm. Los Angeles and Boston are not far behind, each hosting 23 and 22 active trials respectively. These cities offer individuals affected by metastatic lung cancer access to cutting-edge clinical trials that pave the way for advancements in care and provide hope for better outcomes.

Which are the top treatments for metastatic lung cancer being explored in clinical trials?

Metastatic lung cancer research is advancing rapidly, with several promising treatments at the forefront of clinical trials. Pembrolizumab stands out as a leading contender, currently being explored in six active trials dedicated to metastatic lung cancer. Since its initial listing in 2011, it has amassed an impressive 190 all-time trials focused on combating this aggressive disease. Nivolumab closely follows with four ongoing trials and a robust history of 131 all-time metastatic lung cancer studies since its introduction in 2011. Another noteworthy treatment is atezolizumab, presently under investigation in two active trials and boasting an impressive track record of 81 all-time clinical trials since its debut in 2013. Last but not least, paclitaxel brings decades of experience to the table, participating in two current metastatic lung cancer studies alongside an extensive portfolio of 189 previous clinical investigations dating back to 2002. These innovative therapies offer renewed hope for patients battling metastatic lung cancer around the world.

What are the most recent clinical trials for metastatic lung cancer?

Recent clinical trials offer promising prospects for patients with metastatic lung cancer. Among them, the brigimadlin (BI 907828) treatment arm demonstrated encouraging results in Phase 2, highlighting its potential as a therapeutic option. Another trial focused on sitravatinib, aiming to determine its efficacy in treating this aggressive form of cancer. Additionally, BLU-945 underwent both Phase 1 and Phase 2 testing to evaluate its effectiveness against metastatic lung cancer. Further advancements include the investigation of pembrolizumab/vibostolimab in a Phase 3 trial and exploring the benefits of thoracic radiotherapy through another Phase 3 study. These recent breakthroughs bring renewed hope for improved outcomes and enhanced quality of life for individuals battling metastatic lung cancer.

What metastatic lung cancer clinical trials were recently completed?

A multitude of clinical trials investigating potential treatments for metastatic lung cancer have recently concluded, showcasing the ongoing efforts to combat this challenging disease. Noteworthy completed studies include Vergent Bioscience's trial on VGT-309 in May 2022, Erasca Inc.'s trial on ERAS-007 in September 2021, and Mirati Therapeutics Inc.'s trial on MRTX849 in August 2021. Other significant trials that wrapped up earlier include Ociperlimab by BeiGene and Probiotic by Mayo Clinic (both completed July 2021), Berzosertib by EMD Serono Research & Development Institute (completed March 2021), Osimertinib by M.D. Anderson Cancer Center (completed June 2020), and Proton beam therapy RT by Case Comprehensive Cancer Center (completed August 2019).